Stock Events

Caredx 

$13.16
61
-$0.29-2.19% Today

Statistics

Day High
-
Day Low
-
52W High
17.03
52W Low
4.8
Volume
478,472
Avg. Volume
1,060,234
Mkt Cap
685.42M
P/E Ratio
-3.83
Dividend Yield
-
Dividend
-

Earnings

9MayConfirmed
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
-2.21
-1.48
-0.76
-0.03
Expected EPS
-0.19
Actual EPS
-0.03

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CDNA. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Natera
NTRA
Mkt Cap13.45B
Natera offers similar organ transplant care solutions, including non-invasive genetic testing, directly competing with CareDx's offerings.
Illumina
ILMN
Mkt Cap16.96B
Illumina provides genomic sequencing solutions that are foundational to the development of molecular diagnostics in transplantation, similar to CareDx's services.
Exact Sciences
EXAS
Mkt Cap9.2B
Exact Sciences offers cancer screening and diagnostic tests that overlap with CareDx's diagnostic solutions for transplant patients.
Guardant Health
GH
Mkt Cap3.12B
Guardant Health specializes in liquid biopsies and cancer diagnostics, competing in the broader market of molecular diagnostics alongside CareDx.
Qiagen NV
QGEN
Mkt Cap9.98B
Qiagen provides sample and assay technologies for molecular diagnostics, competing with CareDx in the field of genomic testing.
Fulgent Genetics
FLGT
Mkt Cap640.08M
Fulgent Genetics offers comprehensive genetic testing, competing with CareDx in the genomic analysis market, including applications in transplantation.
Bio-Rad Laboratories
BIO
Mkt Cap8.16B
Bio-Rad Laboratories provides a range of products and services for life science research and clinical diagnostics, overlapping with CareDx's market.
Thermo Fisher Scientific
TMO
Mkt Cap222.94B
Thermo Fisher Scientific offers a broad range of solutions for genomic sequencing and analysis, competing with CareDx in the diagnostics and research market.
Quest Diagnostics
DGX
Mkt Cap15.7B
Quest Diagnostics provides diagnostic testing services, including for organ health, indirectly competing with CareDx's transplant diagnostics.

Analyst Ratings

18$Average Price Target
The highest estimate is $22.
From 5 ratings within the last 6 months. This is not an investment recommendation.
Buy
60%
Hold
40%
Sell
0%

About

Health Technology
Medical Specialties
Health Care and Social Assistance
Medical Laboratories
CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company also offers TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution; Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
Show more...
CEO
Peter Maag
Employees
635
Country
US
ISIN
US14167L1035
WKN
000A118WG

Listings